

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts

Batch 42

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No equality issues were raised during consultation. The company requested to amend the proposed remit in line with anticipated wording of marketing authorisation which specified an age cut-off of '65 years or more'.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Attendees understood that final NICE guidance will be issued within the marketing authorisation, however noting the NICE obligations towards people protected by the equality legislation; it was decided that age restriction should not be specified in the remit or the scope.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues

been identified during the scoping process, and, if so, have changes to the matrix been made?
No

Approved by Associate Director (name): ...Frances Sutcliffe.....

Date: 15 September 2015